Cover Image

Cellular modulation and HIV reactivation in response to serial treatment of latently HIV infected CD4 T cells with histone deacetylase inhibitors (HDACi)

Saved in:

Bibliographic Details
Main Authors:	J. Maxwell (Author), A. Nefedov (Author), C. Dorfmeier (Author), G. Wu (Author), Y. Li (Author), P. Zuck (Author), D. Hazuda (Author), A. Webber (Author), R. Barnard (Author), B. Howell (Author)
Format:	Book
Published:	Elsevier, 2019-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

HDACiDB: a database for histone deacetylase inhibitors
by: Murugan K, et al.
Published: (2015)

Design, synthesis, molecular docking study, and biological evaluation of salicylaldimine derivatives as potential histone deacetylases inhibitors (HDACi) and anticancer agents
by: Heba M. Hesham, et al.
Published: (2018)

Mixed effects of HDACi on host gene expression and their implications for HIV reactivation from latency
by: N. Beliakova-Bethell, et al.
Published: (2015)

Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
by: Ana Vuletić, et al.
Published: (2023)

Histone deacetylase inhibitors
by: Marzena Baran, et al.
Published: (2020)

OA3-4 LB Elimination of HIV-1 latently infected cells by PKC agonist gnidimacrin alone and in combination with a histone deacetylase inhibitor
by: L. Huang, et al.
Published: (2016)

36 Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
by: X.T. Kuang, et al.
Published: (2016)

Histone acetylation and the role of histone deacetylases in normal cyclic endometrium
by: Palak Gujral, et al.
Published: (2020)

Clinical Toxicities of Histone Deacetylase Inhibitors
by: Richard L. Piekarz, et al.
Published: (2010)

Medicinal chemistry of histone deacetylase inhibitors
by: Ružić Dušan, et al.
Published: (2021)

PP 1.22 - 00120 Suppression of CD4+ T-cell-intrinsic immunity by HIV-1 latency-reversing HDACi
by: J. Kazmierski, et al.
Published: (2022)

10 Histone deacetylase inhibitors reduce proteins crucial to the elongation, splicing and nuclear export of HIV RNAs
by: Talia M. Mota, et al.
Published: (2017)

Ingenol derivatives are potent reactivators of latent HIV
by: V. Planelles, et al.
Published: (2015)

Zinc binding groups for histone deacetylase inhibitors
by: Lei Zhang, et al.
Published: (2018)

Role of histone deacetylases and their inhibitors in neurological diseases
by: Li-Ying Zhang, et al.
Published: (2024)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
by: H. Miles Prince, et al.
Published: (2010)

Dual Inhibitors Targeting DNA and Histone Deacetylases
by: Chen Chen, et al.
Published: (2020)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
by: Ehab Ghazy, et al.
Published: (2022)

Advanced Progress of Histone Deacetylases in Rheumatic Diseases
by: Liu XM, et al.
Published: (2024)

Sequential treatment with 5-aza-2'deoxycitidine and deacetylase inhibitors reactivates HIV
by: C. Van Lint, et al.
Published: (2015)

Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening
by: Donya Naz Divsalar, et al.
Published: (2020)

Carbocisteine Improves Histone Deacetylase 2 Deacetylation Activity via Regulating Sumoylation of Histone Deacetylase 2 in Human Tracheobronchial Epithelial Cells
by: Yun Song, et al.
Published: (2019)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs.
by: Hugo Rolando Vaca, et al.
Published: (2021)

Analysis of the interactome of Schistosoma mansoni histone deacetylase 8.
by: Stéphanie Caby, et al.
Published: (2017)

Natural Products Impacting DNA Methyltransferases and Histone Deacetylases
by: Sergi Herve Akone, et al.
Published: (2020)

Targeting histone deacetylases for cancer therapy: Trends and challenges
by: Tao Liang, et al.
Published: (2023)

The Role and Mechanism of Histone Deacetylases in Acute Kidney Injury
by: Xun Zhou, et al.
Published: (2021)

Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer
by: Danqi Chen, et al.
Published: (2016)

Research Progress on the Mechanism of Histone Deacetylases in Ferroptosis of Glioma
by: Meng Ma, et al.
Published: (2024)

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
by: Dusan Ruzic, et al.
Published: (2022)

Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
by: Androniki Kretsovali, et al.
Published: (2012)

Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis
by: Ling Nie, et al.
Published: (2020)

Role of mitochondrial antiviral signaling protein in reactivation of latent HIV-1 in CD4+ T cells
by: C.L. Novis, et al.
Published: (2017)

PP 1.35 - 00172 A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV infected cells
by: J. Peterson, et al.
Published: (2022)

Effects of heme degradation products on reactivation of latent HIV-1
by: Z. Melkova, et al.
Published: (2015)

The role of histone deacetylases in human gastrointestinal and associated glands cancer
by: Masumeh Sanaei, et al.
Published: (2019)

Synthesis and Crystal Structure Analysis of Histone Deacetylase Inhibitor Chidamide
by: Bo Han, et al.
Published: (2023)

Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils
by: Adcock Ian M, et al.
Published: (2010)

Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps
by: Wenli Fan, et al.
Published: (2021)

Unveiling the role of histone deacetylases in neurological diseases: focus on epilepsy
by: Dan-Feng Cao, et al.
Published: (2024)